GSK plc
GSK- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 1,048 institutions reported holding it in 13F filings for Q2 2026, worth $18.2B in total; no superinvestor holds it.
Other share classesGLAXF
Q2 2021 vs. Q1 2021
How the institutions holding GSK plc changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 778 | 7 | 803 | +32 |
| Shares | 316.7M | 1.69M | 319.4M | +4.41M (+1.4%) |
| Value | $11.3B | $60.3M | $12.7B | +$1.48B (+13.1%) |
7 institutions that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (95)
Institutions that held GSK plc at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (63)
Institutions that held GSK plc at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (7)
Institutions that held GSK plc at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Waddell & Reed Financial Inc | 1,520,795 | $54.3M |
| Bokf, NA | 100,589 | $3.59M |
| Rikoon Group, LLC | 28,404 | $1.03M |
| Elevated Capital Advisors, LLC | 16,824 | $634.0K |
| Money Concepts Capital Corp | 16,986 | $606.0K |
| Sullivan, Bruyette, Speros & Blaney, LLC | 3,395 | $121.0K |
| Tompkins Financial Corp | 1,600 | $57.0K |